An authorized generic of Paraplatin was sold before, but it isn’t sold now. Ask your pharmacist whether a regular generic (carboplatin) is available.
Source: FDA, updated October 30, 2026
How to pay the least
Ask for the cash price
Generic carboplatin
No pharmacy we check posts a price for it.
- Ask your pharmacy for the cash price of generic carboplatin.Find pharmacies near you
- Ask one or two other pharmacies too. Cash prices for the same generic can differ a lot from store to store.
A regular generic has the same active ingredient as Paraplatin, and the FDA requires it to work the same way.
Compare every option
Question
Brand nameParaplatin
Authorized genericcarboplatin
Regular genericcarboplatin
What you’d pay
Not soldNo longer sold
Not soldNo longer sold
Cash priceAsk the pharmacy
Same as Paraplatin?
–
–
Same active ingredientFillers and dyes can differ
Details for each option
Details for
Brand nameNot sold
Paraplatin itself isn’t sold as a prescription anymore. Its generic versions, if any, are in the other tabs.
Authorized genericNot sold now
Regular genericWho makes it
5 companies sell a generic of Paraplatin that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
It’s mostly filled by specialty pharmacies. Your prescriber’s office or insurer can tell you which one to use.
-
Apotex10 mg/mL
Made by Teyro Labs · Being phased out; sold until November 2027
How it looks, what’s in it, NDCs
10 mg/mL
Package NDC Carton of 5 mL 60505-6282-1 Carton of 15 mL 60505-6282-3 Carton of 45 mL 60505-6282-6 Carton of 60 mL 60505-6282-7 Inactive ingredients: water
-
Eugia450 mg/45 mL, 600 mg/60 mL
How it looks, what’s in it, NDCs
450 mg/45 mL
Package NDC Carton of 45 mL 55150-335-00 450 mg/45 mL
Package NDC Carton of 45 mL 55150-335-01 600 mg/60 mL
Package NDC Carton of 60 mL 55150-386-00 600 mg/60 mL
Package NDC Carton of 60 mL 55150-386-01 Inactive ingredients: mannitol, water
-
Fresenius Kabi10 mg/mL
-
Hospira10 mg/mL
How it looks, what’s in it, NDCs
10 mg/mL
Package NDC Carton of 15 mL 61703-150-05 10 mg/mL
Package NDC Carton of 45 mL 61703-262-05 10 mg/mL
Package NDC Carton of 5 mL 61703-339-18 Carton of 15 mL 61703-339-22 Carton of 45 mL 61703-339-50 Carton of 60 mL 61703-339-56 10 mg/mL
Package NDC Carton of 60 mL 61703-600-05 Inactive ingredients: water
-
Teva Parenteral Medicines10 mg/mL
Made by Pharmachemie
How it looks, what’s in it, NDCs
10 mg/mL
Package NDC Carton of 60 mL 0703-4239-81 10 mg/mL
Package NDC Carton of 60 mL 0703-4239-01 10 mg/mL
Package NDC Carton of 5 mL 0703-4244-81 10 mg/mL
Package NDC Carton of 5 mL 0703-4244-01 10 mg/mL
Package NDC Carton of 15 mL 0703-4246-81 10 mg/mL
Package NDC Carton of 15 mL 0703-4246-01 10 mg/mL
Package NDC Carton of 45 mL 0703-4248-01 10 mg/mL
Package NDC Carton of 45 mL 0703-4248-81 Inactive ingredients: mannitol, water
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
What it’s used for
What the FDA label says
Initial Treatment of Advanced Ovarian Carcinoma
Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ).
There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup.
Secondary Treatment of Advanced Ovarian Carcinoma
Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.
Source: the FDA label for Carboplatin (Teva Parenteral Medicines, Inc.), August 30, 2022. Full label on DailyMed
Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/paraplatin/